Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 541 to 555 of 913 results for death

  1. Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA1005)

    Evidence-based recommendations on futibatinib (Lytgobi) for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.

    Technology appraisal guidance
    Published
    11 September 2024

    Sections for TA1005

  2. Bortezomib and thalidomide for the first‑line treatment of multiple myeloma (TA228)

    Evidence-based recommendations on bortezomib (Velcade) and thalidomide (Thalidomide Celgene) for treating multiple myeloma in adults.

    Technology appraisal guidance
    Published
    27 July 2011
    View recommendations

    Sections for TA228

  3. Pharyngeal electrical stimulation for neurogenic dysphagia (IPG781)

    Evidence-based recommendations on pharyngeal electrical stimulation for neurogenic dysphagia. This involves passing a catheter through the nose and into the throat where it is used to deliver small amounts of electrical current. The current travels from the throat to the brain and stimulates the areas involved in swallowing.

    Interventional procedures guidance
    Published
    23 January 2024
    View recommendations

    Sections for IPG781

  4. Preventing excess weight gain (NG7)

    This guideline covers behaviours such as diet and physical activity to help children (after weaning), young people and adults maintain a healthy weight or help prevent excess weight gain. The aim is to prevent a range of diseases and conditions including cardiovascular disease and type 2 diabetes and improve mental wellbeing.

    NICE guideline
    Published
    13 March 2015
    View recommendations

    Sections for NG7

  5. Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)

    This guideline covers interventions in the acute stage of a stroke or transient ischaemic attack (TIA). It offers the best clinical advice on the diagnosis and acute management of stroke and TIA in the 48 hours after onset of symptoms.

    NICE guideline
    Last updated
    13 April 2022
    View recommendations

    Sections for NG128

  6. Reducing the risk of complications of anticancer treatment in children and young people, and in adults diagnosed with lymphoma:- Randomised studies should investigate primary prophylaxis of neutropenic sepsis in 2 populations: children and young people (aged under 18) having treatment for solid tumours or haematological malignancies, or stem cell transplantation; and adults (aged 18 and older) diagnosed with lymphoma. The studies should compare the effectiveness of fluoroquinolone antibiotics given alone, fluoroquinolone antibiotics given together with G-CSF preparations, and G-CSF preparations given alone. Outcome measures should include overall mortality, infectious episodes and adverse events. In addition, quality of life should be determined using quantitative and qualitative methods. The resulting data should be used to develop a cost-effectiveness analysis comparing these 3 forms of prophylaxis in children and young people having anticancer treatment, and in adults diagnosed with lymphoma.

    medication. The effects of these differences are not known, but it is known that death rates from neutropenic sepsis are higher in...

    Research recommendation
    Published
    9 June 2015

  7. Recognising dying:- What can multiprofessional teams do to reduce the impact of uncertainty of recognising when a person is entering the last days of life on clinical care, shared decision-making and communication with the dying person and those important to them?

    identification and/or achievement of patient wishes such as preferred place of death. In addition the barriers and facilitators for the...

    Research recommendation
    Published
    27 January 2016

  8. Cancer: bowel screening (60 to 74 years) (IND64)

    This indicator covers the proportion of eligible people aged 60 to 74 years whose record shows a bowel screening test has been performed within the last 2.5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG83

    Network / system level indicators
    Last updated
    31 October 2023

  9. Balloon kyphoplasty for vertebral compression fractures (IPG166)

    Evidence-based recommendations on balloon kyphoplasty for vertebral compression fractures. This involves inflating baloon-like devices placed into the collapsed vertebra until it reaches normal height, after which they are removed and replaced with a special cement.

    Interventional procedures guidance
    Published
    26 April 2006
    View recommendations

    Sections for IPG166

  10. Bulevirtide for treating chronic hepatitis D (TA896)

    Evidence-based recommendations on bulevirtide (Hepcludex) for chronic hepatitis D in adults.

    Technology appraisal guidance
    Published
    7 June 2023
    View recommendations

    Sections for TA896

  11. Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy (TA827)

    Evidence-based recommendations on azacitidine (Onureg) for maintenance treatment of acute myeloid leukaemia after induction therapy in adults.

    Technology appraisal guidance
    Published
    5 October 2022
    View recommendations

    Sections for TA827

  12. DuraGraft for preserving vascular grafts (MIB184)

    NICE has developed a medtech innovation briefing (MIB) on DuraGraft for preserving vascular grafts .

    Medtech innovation briefing
    Published
    8 May 2019

  13. Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705)

    Evidence-based recommendations on atezolizumab (Tecentriq) for treating advanced non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    2 June 2021
    View recommendations

    Sections for TA705

  14. Designing systems for documenting drug allergy:- Which documentation strategies would be most clinically and cost effective to minimise the number of people who are re-exposed to drugs to which they have a suspected or confirmed allergy, looking in particular at: - electronic health records that include features specifically designed to record and alert clinicians to drug allergy information, compared with systems without such features and - different formats for patient-held, structured drug allergy documentation?

    the majority of people, a minority of these incidents have caused harm or death. The systematic review undertaken for this guideline...

    Research recommendation
    Published
    9 June 2015

  15. Treatment of convulsive status epilepticus (that is, not just refractory): What is the most effective and safest AED to treat: established (usually lasting longer than 30 minutes) convulsive status epilepticus refractory convulsive status epilepticus?

    complicated by irreversible neurological and intellectual sequelae, including death. Reasons for these complications include the...

    Research recommendation
    Published
    13 August 2021